Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p11
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 11/16)
Character Range: 147125–149994

disease, in packs containing not more than 7 days' supply.
LEVOCABASTINE in topical eye or nasal preparations.
LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
 (a) in a primary pack containing not more than 5 days' supply; and
 (b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LIDOCAINE in preparations for topical use other than eye drops:
 (a) containing 10% or less of total local anaesthetic substances, except:

          (i) in dermal preparations containing 2% or less of total local anaesthetic substances; or

          (ii) in aqueous sprays for oromucosal use containing 0.6% or less of total local anaesthetic substances; or
 (b) in divided preparations containing 200 mg or less of total local anaesthetic substances, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2% or less of lindane.
LITHIUM in preparations for dermal use containing 1% or less of lithium except:
 (a) when present as an excipient at 0.25% or less of lithium; or
 (b) in preparations containing 0.01% or less of lithium.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis when:
 (a) in a primary pack containing 10 dosage units or less when labelled for adults and children 6 years and over; and
 (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2% or less of mercurochrome except when included in Schedule 6.
MERCURY for external use in preparations containing 0.5% or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1% or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the